Baidu
map

日本厚生劳动省批准Vadadustat治疗慢性肾病引起的贫血

2020-06-30 Allan MedSci原创

生物制药公司Akebia Therapeutics今日宣布,日本厚生劳动省已批准缺氧诱导因子脯氨酰羟化酶抑制剂vadadustat用于治疗慢性肾脏疾病(CKD)引起的贫血。

生物制药公司Akebia Therapeutics今日宣布,日本厚生劳动省已批准缺氧诱导因子脯氨酰羟化酶抑制剂vadadustat用于治疗慢性肾脏疾病(CKD)引起的贫血。Akebia的合作伙伴三菱田边制药公司(MTPC)已获得vadadustat的生产和销售许可,vadadustat将由MTPC在日本以商品名VAFSEO销售。

在日本,约有1300万人患有晚期CKD。贫血常见于CKD患者,其患病率随着CKD的发展而增加。除了引起致残性症状以外,重度贫血可能影响非透析CKD患者和透析患者的血管功能。对于非透析CKD患者,重度贫血可能加快终末期肾病(end-stage renal disease,ESRD)的进展。注射式促红细胞生成剂(ESA)是目前的护理标准。Vadadustat将为成年患者提供了一种便捷的口服治疗剂。

Akebia总裁兼首席执行官John P. Butler表示:“对于因CKD导致的贫血患者而言,Vadadustat的获批将对日本患者带来显著益处。预计vadadustat将在今年晚些时候在日本实现商业化”。

 

原始出处:

https://www.firstwordpharma.com/node/1736458?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752377, encodeId=c4a01e523771b, content=<a href='/topic/show?id=470018253b1' target=_blank style='color:#2F92EE;'>#vadadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18253, encryptionId=470018253b1, topicName=vadadustat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f93736519237, createdName=zhucaizhong7778, createdTime=Sat Aug 29 01:28:33 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264752, encodeId=1c291264e527c, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294554, encodeId=14b4129455426, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368745, encodeId=cf4a1368e451a, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800642, encodeId=02078006424a, content=可以可以!, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73ac5259421, createdName=风湿免疫科医生, createdTime=Tue Jun 30 22:30:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800633, encodeId=41b9800633e6, content=罗沙司他竞品, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Tue Jun 30 21:39:43 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1752377, encodeId=c4a01e523771b, content=<a href='/topic/show?id=470018253b1' target=_blank style='color:#2F92EE;'>#vadadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18253, encryptionId=470018253b1, topicName=vadadustat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f93736519237, createdName=zhucaizhong7778, createdTime=Sat Aug 29 01:28:33 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264752, encodeId=1c291264e527c, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294554, encodeId=14b4129455426, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368745, encodeId=cf4a1368e451a, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800642, encodeId=02078006424a, content=可以可以!, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73ac5259421, createdName=风湿免疫科医生, createdTime=Tue Jun 30 22:30:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800633, encodeId=41b9800633e6, content=罗沙司他竞品, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Tue Jun 30 21:39:43 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
    2020-07-02 般若傻瓜
  3. [GetPortalCommentsPageByObjectIdResponse(id=1752377, encodeId=c4a01e523771b, content=<a href='/topic/show?id=470018253b1' target=_blank style='color:#2F92EE;'>#vadadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18253, encryptionId=470018253b1, topicName=vadadustat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f93736519237, createdName=zhucaizhong7778, createdTime=Sat Aug 29 01:28:33 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264752, encodeId=1c291264e527c, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294554, encodeId=14b4129455426, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368745, encodeId=cf4a1368e451a, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800642, encodeId=02078006424a, content=可以可以!, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73ac5259421, createdName=风湿免疫科医生, createdTime=Tue Jun 30 22:30:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800633, encodeId=41b9800633e6, content=罗沙司他竞品, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Tue Jun 30 21:39:43 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1752377, encodeId=c4a01e523771b, content=<a href='/topic/show?id=470018253b1' target=_blank style='color:#2F92EE;'>#vadadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18253, encryptionId=470018253b1, topicName=vadadustat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f93736519237, createdName=zhucaizhong7778, createdTime=Sat Aug 29 01:28:33 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264752, encodeId=1c291264e527c, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294554, encodeId=14b4129455426, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368745, encodeId=cf4a1368e451a, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800642, encodeId=02078006424a, content=可以可以!, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73ac5259421, createdName=风湿免疫科医生, createdTime=Tue Jun 30 22:30:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800633, encodeId=41b9800633e6, content=罗沙司他竞品, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Tue Jun 30 21:39:43 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1752377, encodeId=c4a01e523771b, content=<a href='/topic/show?id=470018253b1' target=_blank style='color:#2F92EE;'>#vadadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18253, encryptionId=470018253b1, topicName=vadadustat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f93736519237, createdName=zhucaizhong7778, createdTime=Sat Aug 29 01:28:33 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264752, encodeId=1c291264e527c, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294554, encodeId=14b4129455426, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368745, encodeId=cf4a1368e451a, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800642, encodeId=02078006424a, content=可以可以!, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73ac5259421, createdName=风湿免疫科医生, createdTime=Tue Jun 30 22:30:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800633, encodeId=41b9800633e6, content=罗沙司他竞品, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Tue Jun 30 21:39:43 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
    2020-06-30 风湿免疫科医生

    可以可以!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1752377, encodeId=c4a01e523771b, content=<a href='/topic/show?id=470018253b1' target=_blank style='color:#2F92EE;'>#vadadustat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18253, encryptionId=470018253b1, topicName=vadadustat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f93736519237, createdName=zhucaizhong7778, createdTime=Sat Aug 29 01:28:33 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264752, encodeId=1c291264e527c, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294554, encodeId=14b4129455426, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368745, encodeId=cf4a1368e451a, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jul 02 12:28:33 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800642, encodeId=02078006424a, content=可以可以!, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73ac5259421, createdName=风湿免疫科医生, createdTime=Tue Jun 30 22:30:09 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800633, encodeId=41b9800633e6, content=罗沙司他竞品, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Tue Jun 30 21:39:43 CST 2020, time=2020-06-30, status=1, ipAttribution=)]
    2020-06-30 mswert122

    罗沙司他竞品

    0

相关资讯

FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血

百时美施贵宝公司(Bristol Myers Squibb)近日宣布,FDA已扩大Reblozyl(luspatercept-aamt)的适应症范围。

J Periodontol:牙周炎可引起炎症性贫血

尽管白细胞增多症是严重牙周炎的常见特征,但关于牙周炎中红细胞计数的证据较少,这表明可能出现贫血趋势。本研究旨在调查牙周炎与循环白细胞,红细胞和血小板之间的关联。

Blood:老年贫血个体的突变谱和克隆造血动态

中心点:特异性突变,包括TP53和SF3B1,在老年贫血个体中富集,但不包括DNMT3A、TET2和ASXL1。一般来说,随着时间的推移,克隆只会带来有限的选择优势,这与特定的驱动基因有差异。摘要:贫血是一种造血老化的主要的、目前知之甚少的临床表现。随着年龄增长,携带获得性白血病相关突变的造血克隆扩增到可被检测到,被称为克隆造血(CH)。为了研究老年贫血与CH的关系,Zeventer等人对老年贫血

JAMA:静脉铁输注对缺铁性贫血患者低磷血症的影响

研究发现,对于口服铁制剂不耐受的缺铁性贫血患者,注射异麦芽糖酐铁导致的低磷血症风险显著低于羧基麦芽糖铁

Blood:可抑制血小板吞噬作用的抗体,或可治疗ITP

红细胞抗体诱导性贫血并不是预测ITP小鼠模型治疗成功的抗体的充分条件。 体外成功阻断血小板吞噬的红细胞特异性抗体可改善ITP小鼠的ITP症状。

Astellas在日本提交roxadustat的补充新药申请,用于治疗慢性肾脏疾病相关贫血

Astellas与合作伙伴FibroGen共同向日本厚生劳动省提交了补充新药申请(sNDA),以获取roxadustat的上市许可,用于治疗与非透析患者慢性肾脏疾病(CKD)相关的贫血。

拓展阅读

Ren Fail:我国学者揭示高超加工食品摄入显著增加慢性肾病的发病风险

高超加工食品摄入量显著增加了CKD的发病风险,进一步支持了饮食模式在CKD防控中的重要作用。

慢性肾病:美国在研的130项基金项目,关注这些热点(2024)

我们仅对美国国立卫生研究院(NIH)资助的在研慢性肾病相关项目进行梳理,希望给同仁们的选题思路提供一点启发。

Ann Rheum Dis:生物制剂在类风湿性关节炎伴慢性肾病患者中的疗效与安全性

生物制剂在RA伴CKD患者中的疗效和安全性得到证实。

慢性肾病患者肾功能衰竭的风险评分(KFREs评分)

慢性肾病患者肾功能衰竭的风险评分(KFREs评分)

FLOW试验预先指定分析研究结果公布! 司美格鲁肽降低2型糖尿病和慢性肾病患者的心衰风险 | ESC 2024

研究提示司美格鲁肽可降低2型糖尿病合并慢性肾病患者的心衰风险。

慢性肾病患者5年肾功能衰竭的风险模型(KFREs精确计算模型)

慢性肾病患者5年肾功能衰竭的风险模型(KFREs精确计算模型)

Baidu
map
Baidu
map
Baidu
map